Zirn v. VLI Corp.

621 A.2d 773, 1993 Del. LEXIS 112
CourtSupreme Court of Delaware
DecidedMarch 8, 1993
StatusPublished
Cited by76 cases

This text of 621 A.2d 773 (Zirn v. VLI Corp.) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Zirn v. VLI Corp., 621 A.2d 773, 1993 Del. LEXIS 112 (Del. 1993).

Opinion

WALSH, Justice:

This is an appeal from a decision of the Court of Chancery in a class action initiated by Marilyn Zirn (“Zirn”), a shareholder of VLI Corporation (“VLI”). Zirn appeals from a post-trial determination that the defendants-appellees did not breach their duty of disclosure or commit equitable fraud in connection with the merger of VLI with American Hospital Corporation (“AHP”). 1 We conclude that the Court of Chancery erred in its application of the standard for determining the materiality of disclosure to shareholders in a merger context. We further conclude that the Trial Court erred in restricting discovery by Zirn into advice given VLI by its new patent counsel regarding a matter which was material to the merger negotiations. Accordingly, we reverse and remand for further proceedings.

I

Until its merger into AHP in December 1987, VLI manufactured and marketed a variety of contraceptives and related products, including its chief product, an over-the-counter female contraceptive known as the Today® Vaginal Contraceptive Sponge (the “Sponge”). The Sponge’s unique contraceptive technology was protected by its FDA New Drug Approval Status and by a United States patent which had been issued on July 19, 1983 (“patent”).

In 1985, the management of VLI determined that an acquisition of the company was necessary if it were to remain financially viable. After an extensive two-year search in which at least 40 companies were approached, the only potential buyer to express serious interest in acquiring VLI as an entity was AHP, a leading marketer of over-the-counter pharmaceutical products.

Representatives of VLI and AHP met in late August, 1987 to discuss the acquisition. Initially, AHP offered VLI $7.00 per share in the form of a tender offer for all of its outstanding shares. Shortly before the parties met to draft the tender offer agreement, however, VLI learned that its patent on the Sponge had lapsed due to an inadvertent failure to pay a maintenance fee. This was disclosed to AHP on August 28, 1987.

In response to the loss of the patent, the form of the transaction was changed from a tender offer/merger to a merger, although the amount of consideration remained unchanged. In addition, reinstatement of the patent was made a condition of consummation of the transaction. Either party could terminate the agreement if the merger were not consummated by March 1, 1988. After receiving an investment banker’s opinion that $7.00 per share was fair to its shareholders, the VLI Board of Directors (“VLI Board”) approved the merger agreement on August 30, 1987 and the proposed merger was announced the following day.

On September 3, 1987, VLI’s patent counsel petitioned the United States Patent and Trademark Office (“Patent Office”) for reinstatement of the patent. The Patent Office denied the petition on September 21, 1987. VLI obtained new patent counsel and filed a petition for reconsideration of the denial on October 21, 1987. Throughout this period, VLI’s new patent counsel *776 was of the opinion that there was a “significant possibility” that the petition for reconsideration would be unsuccessful.

On October 19, 1987, the Dow Jones Industrial Average fell more than 500 points. Stock values in markets around the world plummeted dramatically on that day and in the days that followed. VLI’s stock, which had been trading in the range of $4-% to $5-% in the week prior to the decline, reached a low of $3-% on October 26, 1987.

Prior to the market decline, AHP had been conducting a due diligence review of VLI. The review was basically completed by September 30, 1987, but AHP was awaiting VLI’s financial reports for the third quarter of 1987. VLI made a partial announcement of its third quarter performance in a press release issued on October 8, 1987 in which it disclosed net income of $.04 per share, an increase of $.32 per share from third quarter 1986. However, on October 22, 1987, AHP received more complete information concerning VLI’s third quarter financial results. These results revealed a larger than expected decline of 22 percent in Sponge sales from 1986 third quarter levels. Zirn contends that AHP’s Board of Directors did not learn of the drop in Sponge sales until November, 1987.

In any event, on October 27, 1987, AHP determined that it should attempt to renegotiate the August 30 merger agreement. In a meeting with VLI representatives on November 1,1987, AHP proposed the elimination of the patent reinstatement condition, a change in the form of the acquisition from a merger to a tender offer/merger and a reduction in the purchase price from $7.00 per share to $6.25 per share.

The VLI Board met on November 3,1987 to consider AHP’s modified offer. The VLI Board discussed the lack of any other suitor, VLI’s continuing need for an infusion of capital, the turmoil in the financial markets due to the October crash and the possibility that the patent would not be reinstated. After receiving an investment banker’s opinion that $6.25 per share was fair to its shareholders, the VLI Board accepted the proposal.

VLI soon began distributing materials to its shareholders, recommending that they tender their shares to AHP. The material included: (i) a letter from VLI’s Chief Executive Officer, announcing the $6.25 per share tender offer; (ii) the Schedule 14D-9 filed with the Securities and Exchange Commission by VLI; and (iii) AHP’s Offer to Purchase. AHP’s Offer to Purchase stated that AHP’s purpose in making the tender offer was to “facilitate the acquisition of [VLI] by AHP,” and the purpose of the subsequent cash-out merger was “to acquire all outstanding shares not tendered and purchased pursuant to the Offer, thereby completing the acquisition of all the Shares.”

VLI’s Schedule 14D-9 explained the lapse of the patent and that VLI’s new patent counsel had advised VLI that “there is a significant possibility of the reconsideration petition not prevailing....” The 14D-9 further stated that

[i]n order to eliminate unsatisfied and uncertain conditions to the August 30 Merger Agreement, which are unsatisfied, to resolve uncertainty, reduce potential delay and increase the prospects that [VLI] will in fact be acquired by [AHP], [VLI’s] Board of Directors after consultation with [VLI’s] financial and legal advisors, determined to accept AHP’s proposal.

On November 17, 1987, Zirn made written demand upon VLI that the company bring suit against VLI’s original patent counsel, general corporate counsel and those responsible for overseeing the maintenance of VLI’s patents. The VLI Board established a special committee (“Special Committee”) to investigate the patent lapse and respond to Zirn’s demand. After conducting an investigation, the Special Committee, consisting of three non-management directors, recommended to the VLI Board that it take no action over the failure to pay the maintenance fee. The Special Committee’s counsel informed Zirn of the recommendation by letter. In his letter, the Special Committee’s counsel quoted VLI’s new patent counsel as having told the Special Committee that there was a *777 “sound factual basis for claiming that the failure to pay the maintenance fee was unavoidable.”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Oracle Corporation Derivative Litigation
Supreme Court of Delaware, 2025
Richard J. Tornetta v. Elon Musk
Court of Chancery of Delaware, 2024
CCSB Financial Corp. v. Deann M. Totta
Supreme Court of Delaware, 2023
Matthew M. Bruckel, MD v. TAUC Holdings, LLC
Court of Chancery of Delaware, 2023
Ghio v. Liberty Ins. Underwriters, Inc.
212 Conn. App. 754 (Connecticut Appellate Court, 2022)
Peter SerVaas v. Ford Smart Mobility LLC
Court of Chancery of Delaware, 2021
Drachman v. BioDelivery Sciences International, Inc.
Court of Chancery of Delaware, 2021
In re Oracle Corporation Derivative Litigation
Court of Chancery of Delaware, 2020
Simon Ogus v. SportTechie, Inc.
Court of Chancery of Delaware, 2020
The Cirillo Family Trust v. Aram Moezinia
Court of Chancery of Delaware, 2018
Morrison v. Berry
191 A.3d 268 (Supreme Court of Delaware, 2018)
Paul Morris v. Spectra Energy Partners (DE) GP
Court of Chancery of Delaware, 2018
Continental Casualty Company v. BorgWarner Inc.
Superior Court of Delaware, 2016
In Re Volcano Corporation Stockholder Litigation
143 A.3d 727 (Court of Chancery of Delaware, 2016)
In Re: Queen's University at Kingston
820 F.3d 1287 (Federal Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
621 A.2d 773, 1993 Del. LEXIS 112, Counsel Stack Legal Research, https://law.counselstack.com/opinion/zirn-v-vli-corp-del-1993.